Our mission is to move breakthrough research to the patient by bringing the best in modern drug discovery to the service of academic medicine. By eliminating roadblocks like loss of control of the research or the challenges of risky fundraising, Bridge Medicines charges head on at major, modern diseases by moving transformational ideas forward. Our ship of expert pirates moves with agility, unencumbered by bureaucracy and full of courage: willing to take risks that reap greater rewards. This is where the promise of our mission comes to life.


Acute Myeloid Leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood, interfering with normal blood cells. AML progresses rapidly and is typically fatal within weeks or months if left untreated. Current standard of care is chemotherapy, followed by radiation therapy or stem cell transplant. In 2015, AML affected about one million people and resulted in 147,000 deaths globally, and accounts for about 1.8% of cancer deaths in the United States.


Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction of the airway. About one-third of people with this condition develop a non-itchy rash called erythema marginatum during an attack.


Find out if your program qualifies for participation in the Bridge Medicines model.